<DOC>
	<DOCNO>NCT00096291</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin paclitaxel , work different way stop tumor cell divide stop grow die . Giving chemotherapy surgery may shrink tumor remove may kill tumor cell remain surgery . PURPOSE : This randomized phase II trial compare two different regimen doxorubicin paclitaxel see well work treat woman undergo surgery breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Using Doxorubicin Paclitaxel Treating Women With Large Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether tumor woman palpable invasive breast cancer wild type p53 sensitive doxorubicin paclitaxel give sequential single-agent neoadjuvant chemotherapy . - Determine whether tumor inactivate p53 sensitive paclitaxel doxorubicin give sequential single-agent neoadjuvant chemotherapy patient . Secondary - Correlate biological marker ( physiological molecular ) tumor response patient treat regimen . - Determine change biological marker neoadjuvant chemotherapy patient . - Compare breast MRI , term assess tumor response , physical exam , mammogram , ultrasound patient treat regimen . - Determine whether MRI indicator ( e.g. , tumor morphology lesion enhancement ) predictive response patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord tumor size ( &gt; 5 cm v ≤ 3-5 cm ) presence palpable regional lymph node ( yes v ) . Patients randomize 1 2 treatment arm . All patient undergo biopsy , bilateral mammogram , MRI , ultrasound , blood marker , molecular ( gene microarrays functional p53 status ) , physiologic study initiation neoadjuvant chemotherapy . Some study repeat completion treatment first chemotherapeutic agent completion treatment second chemotherapeutic agent outline . - Arm I : Patients receive doxorubicin IV day 1 , 15 , 29 , 43 . Patients residual tumor ( indicated clinical evaluation radiologic study ) completion doxorubicin undergo definitive surgery . After surgery , patient receive paclitaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . Patients residual tumor &gt; 2 cm completion doxorubicin undergo 8-12 core needle biopsy . Patients residual tumor &lt; 2 cm completion doxorubicin undergo 4-6 core needle biopsy . After core needle biopsy , patient receive paclitaxel . - Arm II : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . Patients residual tumor ( indicated clinical evaluation radiologic study ) completion paclitaxel undergo definitive surgery . After surgery , patient receive doxorubicin IV day 1 , 15 , 29 , 43 . Patients residual tumor &gt; 2 cm completion paclitaxel undergo 8-12 core needle biopsy . Patients residual tumor &lt; 2 cm completion paclitaxel undergo 4-6 core needle biopsy . After core needle biopsy , patient receive doxorubicin . In arm , treatment continue absence disease progression unacceptable toxicity . Samples core needle biopsy analyze microarray analysis gene expression profile . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study within 4-5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis invasive breast cancer Tumor ≥ 3 cm palpable Multiple mass allow provide least 1 mass ≥ 3 cm Clinically positive axillary supraclavicular lymph node allow Fine needle aspiration core needle biopsy positive invasive breast cancer AND/OR fine needle aspiration lymph node positive HER2/neupositive OR negative No inflammatory breast cancer No distant metastases Hormone receptor status : Estrogen receptor ( ER ) positive OR ERnegative PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Premenopausal postmenopausal Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT ≤ 2 time ULN Renal Not specify Cardiovascular LVEF ≥ 50 % No congestive heart failure No serious conduction system abnormality No significant cardiovascular disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patients prior concurrent malignancy allow provide receive prior chemotherapy AND likely cure prior malignancy No severe medical psychiatric condition would preclude study compliance No known HIV positivity PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy No prior hormonal therapy breast cancer Radiotherapy No prior radiotherapy malignancy Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>